{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:23:01Z","timestamp":1790482981318,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA044971"],"award-info":[{"award-number":["R01 DA044971"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The United States is currently facing an opioid overdose crisis. Research suggests that multiple interventions are needed to reduce overdose deaths including increasing access and retention to medications to treat opioid use disorders (MOUD, i.e., methadone, buprenorphine, and naltrexone) and increasing the distribution and use of naloxone, a medication that can reverse the respiratory depression that occurs during opioid overdoses. However, barriers to MOUD initiation and retention persist and discontinuations of MOUD carry a heightened risk of overdose. Many times, MOUD is not sought as a first line of treatment by people with opioid use disorder (OUD), many of whom seek treatment from medically managed withdrawal (detox) programs. Among those who do initiate MOUD, retention is generally low. The present study examines the treatment experiences of people who use opioids in three states, Connecticut, Kentucky, and Wisconsin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted in-depth interviews with people who use opioids in a rural, urban, and suburban area of three states: Connecticut, Kentucky and Wisconsin. Data analysis was collaborative and key themes were identified through multiple readings, coding of transcripts and discussion with all research team members.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Results reveal a number of systemic issues that reduce the likelihood that people initiate and are retained on MOUD including the ubiquity of detox as a first step in drug treatment, abstinence requirements and requiring patients to attend group treatment. MOUD-related stigma was a significant factor in the kinds of treatment participants chose and their experiences in treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Interventions to reduce MOUD stigma are needed to encourage MOUD as a first course of treatment. Eliminating abstinence-based rules for MOUD treatment may improve treatment retention and decrease overdose risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-00964-5","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T15:02:34Z","timestamp":1709046154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["\u201cThey make it too hard and too many hoops to jump\u201d: system and organizational barriers to drug treatment during epidemic rates of opioid overdose"],"prefix":"10.1186","volume":"21","author":[{"given":"Julia","family":"Dickson-Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Krechel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ohlrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Danielle Green","family":"Montaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Weeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Havens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"964_CR1","unstructured":"Centers for Disease Control and Prevention. Opioid overdose: Understanding the epidemic. 2020."},{"key":"964_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cct.2016.06.002","volume":"49","author":"R Schwartz","year":"2016","unstructured":"Schwartz R, Kelly SM, Mitchell SG, Dunlap L, Zarkin GA, Sharma A, O\u2019Grady KE, Jaffe JH. Interim methadone and patient naviagation in jail: Rationale and design of a randomized clinical trial. Contemp Clin Trials. 2016;49:66.","journal-title":"Contemp Clin Trials"},{"key":"964_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","volume":"63","author":"RP Schwartz","year":"2006","unstructured":"Schwartz RP, Highfield DA, Jaffe JH, Brady J, Butler CB, Rouse CO, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63:102\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"964_CR4","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.2105\/ajph.2015.302843","volume":"105","author":"SS Martins","year":"2015","unstructured":"Martins SS, Sampson L, Cerd\u00e1 M, Galea S. Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature. Am J Public Health. 2015;105:e29-49. https:\/\/doi.org\/10.2105\/ajph.2015.302843.","journal-title":"Am J Public Health"},{"key":"964_CR5","unstructured":"NCHS NVSS. Provisional drug overdose death counts; 2022."},{"key":"964_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.drugpo.2017.06.004","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: exploring users\u2019 perceptions of fentanyl-adulterated and -substituted \u201cheroin.\u201d Int J Drug Policy. 2017;46:146\u201355. https:\/\/doi.org\/10.1016\/j.drugpo.2017.06.004.","journal-title":"Int J Drug Policy"},{"key":"964_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15585\/mmwr.mm6834a2","volume":"68","author":"RM Gladden","year":"2019","unstructured":"Gladden RM, O\u2019Donnell JK, Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine\u201425 states, July\u2013December 2017 to Jaunary\u2013June 2018. MMWR Morb Mortal Wkly Rep. 2019;68:737.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"964_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.12.004","volume":"196","author":"Z Dai","year":"2019","unstructured":"Dai Z, Abate MA, Smith GS, Kraner JC, Mock AR. Fentanyl and fentanyl-analog involvement in drug-related deaths. Drug Alcohol Depend. 2019;196:1\u20138. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.12.004.","journal-title":"Drug Alcohol Depend"},{"key":"964_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37259","volume":"4","author":"BP Linas","year":"2021","unstructured":"Linas BP, Savinkina A, Madushani RWMA, Wang J, Yazdi GE, Chatterjee A, Walley AY, Morgan JR, Epstein RL, Assoumou SA, et al. Projected estimates of opioid mortality after community-level interventions. JAMA Open. 2021;4: e2037259.","journal-title":"JAMA Open"},{"key":"964_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson C, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open. 2020;3:66.","journal-title":"JAMA Network Open"},{"key":"964_CR11","first-page":"66","volume":"2","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus pacebo or methadone maintenance for opioid dependence. Chochrane Database Syst Rev. 2014;2:66.","journal-title":"Chochrane Database Syst Rev"},{"key":"964_CR12","unstructured":"SAMHSA. Medication assisted treatment: a standard of care; 2014."},{"key":"964_CR13","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","volume":"105","author":"C Jones","year":"2015","unstructured":"Jones C, Campopiano M, Baldwin G, McCance-Katz EF. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105:e55\u201363.","journal-title":"Am J Public Health"},{"key":"964_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/ADM.0b013e3182312983","volume":"5","author":"ML Kraus","year":"2011","unstructured":"Kraus ML, Alford DP, Katz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011;5:254\u201363.","journal-title":"J Addict Med"},{"key":"964_CR15","unstructured":"World Health Organization. Guidelines for the pschosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organizaiton; 2009."},{"key":"964_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.socscimed.2019.05.027","volume":"232","author":"EF Madden","year":"2019","unstructured":"Madden EF. Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019;232:324\u201331.","journal-title":"Soc Sci Med"},{"key":"964_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108721","volume":"138","author":"MS Anvari","year":"2022","unstructured":"Anvari MS, Kleinman MB, Massey EC, Bradley VD, Felton JW, Belcher AM, Magidson JF. \u201cIn their mind, they always felt less than\u201d: the role of peers in shifting stigma as a barrier to opioid use disorder treatment retention. J Subst Abuse Treat. 2022;138: 108721. https:\/\/doi.org\/10.1016\/j.jsat.2022.108721.","journal-title":"J Subst Abuse Treat"},{"key":"964_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jadohealth.2022.08.026","volume":"72","author":"SM Bagley","year":"2023","unstructured":"Bagley SM, Schoenberger SF, dellaBitta V, Lunze K, Barron K, Hadland SE, Park TW. Ambivalence and stigma beliefs about medication treatment among young adults with opioid use disorder: a qualitative exploration of young adults\u2019 perspectives. J Adolesc Health. 2023;72:105\u201310. https:\/\/doi.org\/10.1016\/j.jadohealth.2022.08.026.","journal-title":"J Adolesc Health"},{"key":"964_CR19","doi-asserted-by":"publisher","first-page":"S954","DOI":"10.1007\/s11606-020-06257-4","volume":"35","author":"K Mackey","year":"2020","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35:S954\u201363.","journal-title":"J Gen Intern Med"},{"key":"964_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jsat.2020.108146","volume":"119","author":"K Cioe","year":"2020","unstructured":"Cioe K, Bondi BE, Easly R, Simard A, Zheng X, Springer SA. A systematic review of patients\u2019 and providers\u2019 perspectives on medications for treatment of opioid use disorder. J Subst Abuse Treat. 2020;119:66.","journal-title":"J Subst Abuse Treat"},{"key":"964_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/08897077.2019.1640833","volume":"40","author":"B Allen","year":"2019","unstructured":"Allen B, Nolan ML, Paone D. Underutilization of medications to treat opiod use disorder: What role does stigma play? Subst Abuse. 2019;40:459\u201365.","journal-title":"Subst Abuse"},{"key":"964_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.15288\/jsad.2015.76.644","volume":"76","author":"HK Knudsen","year":"2015","unstructured":"Knudsen HK. The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the United States: a state-level analysis. J Stud Alcohol Drugs. 2015;76:644\u201354.","journal-title":"J Stud Alcohol Drugs"},{"key":"964_CR23","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.drugalcdep.2016.08.642","volume":"173","author":"HK Knudsen","year":"2017","unstructured":"Knudsen HK, Havens JR, Lofwall MR, Studts JL, Walsh SL. Buprenorphine physician supply: relationship with state-level prescription opioid mortality. Drug Alcohol Depend. 2017;173:S55\u201366.","journal-title":"Drug Alcohol Depend"},{"key":"964_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/08897077.2019.1635959","volume":"41","author":"HK Knudsen","year":"2020","unstructured":"Knudsen HK, Lin L, Lofwall MR. Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: a state-level longitudinal analysis. Subst Abuse. 2020;41:259\u201368.","journal-title":"Subst Abuse"},{"key":"964_CR25","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/ajad.12805","volume":"27","author":"E Weintraub","year":"2018","unstructured":"Weintraub E, Greenblatt AD, Chang J, Himelhoch S, Welsh C. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018;27:612\u20137.","journal-title":"Am J Addict"},{"key":"964_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373","volume":"2","author":"RL Haffajee","year":"2019","unstructured":"Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Open. 2019;2: e196373.","journal-title":"JAMA Open"},{"key":"964_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11920-022-01346-z","volume":"24","author":"H Mahmoud","year":"2022","unstructured":"Mahmoud H, Naal H, Whaibeh E, Smith A. Telehealth-based delivery of medication-assisted treatment for opioid use disorder: a critical review of recent developments. Curr Psychiatry Rep. 2022;24:375\u201386. https:\/\/doi.org\/10.1007\/s11920-022-01346-z.","journal-title":"Curr Psychiatry Rep"},{"key":"964_CR28","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1080\/10826084.2022.2064509","volume":"57","author":"SM Walters","year":"2022","unstructured":"Walters SM, Perlman DC, Guarino H, Mateu-Gelabert P, Frank D. Lessons from the first wave of COVID-19 for improved mediations for opioid use disorder (MOUD) treatment: benefits of easier access, extended take homes, and new delivery modalities. Subst Use Misuse. 2022;57:1144\u201353.","journal-title":"Subst Use Misuse"},{"key":"964_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35:22\u201335.","journal-title":"J Addict Dis"},{"key":"964_CR30","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1111\/add.15574","volume":"116","author":"JH Ching","year":"2021","unstructured":"Ching JH, Owens DK, Trafton JA, Goldhaber-Fiebert JD, Salomon JA. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration. Addiction. 2021;116:3494\u2013503. https:\/\/doi.org\/10.1111\/add.15574.","journal-title":"Addiction"},{"key":"964_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/07067437221136468","author":"A Pilarinos","year":"2022","unstructured":"Pilarinos A, Kwa Y, Joe R, Dong H, Grant C, Fast D, Buxton JA, DeBeck K. Methadone maintenance treatment discontinuation among young people use who opioids in Vancouver, Canada. Can J Psychiatry. 2022. https:\/\/doi.org\/10.1177\/07067437221136468.","journal-title":"Can J Psychiatry"},{"key":"964_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13722-022-00299-1","volume":"17","author":"BE Biondi","year":"2022","unstructured":"Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addict Sci Clin Pract. 2022;17:15. https:\/\/doi.org\/10.1186\/s13722-022-00299-1.","journal-title":"Addict Sci Clin Pract"},{"key":"964_CR33","first-page":"66","volume":"16","author":"T Moses","year":"2022","unstructured":"Moses T, Rhodes GL, Tavakoli E, Christensen CW, Amirsadri A, Greenwald MK. Predictors of retention and drug use among patients with opioid use disorder transferred to a specialty \u201csecond chance\u201d methadone program. Subst Abuse Res Treat. 2022;16:66.","journal-title":"Subst Abuse Res Treat"},{"key":"964_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13722-022-00342-1","volume":"17","author":"J Carter","year":"2022","unstructured":"Carter J, Li Z, Chen H, Greiner M, Bush C, Bhattacharya D, Poley S, Sachdeva N, Crowder JC, Feigal J. Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study. Addict Sci Clin Pract. 2022;17:60. https:\/\/doi.org\/10.1186\/s13722-022-00342-1.","journal-title":"Addict Sci Clin Pract"},{"key":"964_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/add.15879","volume":"117","author":"A Savinkina","year":"2022","unstructured":"Savinkina A, Madushani RWMA, Yazdi GE, Want J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction. 2022;117:66.","journal-title":"Addiction"},{"key":"964_CR36","unstructured":"Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS) 2005\u20132015: State admissions to substance abuse treatment services. In: Rockville: SAMHSA; 2017."},{"key":"964_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.drugalcdep.2006.12.019","volume":"89","author":"JD Wines","year":"2007","unstructured":"Wines JD, Saitz R, Horton NJ, Lloyd-Travaglini CA, Samet JH. Overdose after detoxification: a prospective study. Drug Alcohol Depend. 2007;89:161\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"964_CR38","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.mcna.2020.03.003","volume":"104","author":"M Herscher","year":"2020","unstructured":"Herscher M, Fine M, Navalurkar R, Hirt L, Wang L. Diagnosis and management of opioid use disorder in hospitalized patients. Med Clin N Am. 2020;104:695\u2013708.","journal-title":"Med Clin N Am"},{"key":"964_CR39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12889-018-5982-8","volume":"18","author":"H Zhu","year":"2018","unstructured":"Zhu H, Wu L-T. National trends and characteristics of inpatient detoxification for drug use disorders in the United States. BMC Public Health. 2018;18:66.","journal-title":"BMC Public Health"},{"key":"964_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.drugalcdep.2017.11.009","volume":"183","author":"A Acevedo","year":"2018","unstructured":"Acevedo A, Lee MT, Garnick DW, Horgan CM, Ritter GA, Panas L, Campbell K, Bean-Mortinson J. Agency-level financial incentives and electronic remiders to improve continuity of care after discharge from residential treatment and detoxification. Drug Alcohol Depend. 2018;183:192\u2013200.","journal-title":"Drug Alcohol Depend"},{"key":"964_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1037\/a0014205","volume":"23","author":"BK Campbell","year":"2009","unstructured":"Campbell BK, et al. Facilitating outpatient treatment entry following detoxification for injection drug use: a multisite test of three interventions. Psychol Addict Behav. 2009;23:260\u201370.","journal-title":"Psychol Addict Behav"},{"key":"964_CR42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/10550887.2011.554776","volume":"30","author":"E Carrier","year":"2011","unstructured":"Carrier E, et al. Factors associated with frequent utlization of crisis substance use detoxification services. J Addict Dis. 2011;30:116\u201322.","journal-title":"J Addict Dis"},{"key":"964_CR43","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jsat.2006.05.019","volume":"31","author":"TL Mark","year":"2006","unstructured":"Mark TL, Vandivort-Warren R, Montejano LB. Factors affecting detoxification readmission: analysis of pubic sector data from three states. J Subst Abuse Treat. 2006;31:439\u201345.","journal-title":"J Subst Abuse Treat"},{"key":"964_CR44","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1007\/s10461-018-2138-x","volume":"22","author":"CT Lee","year":"2018","unstructured":"Lee CT, Winquist A, Wiewel EW, Braunstein S, Jordan HT, Gould LH, Gwynn RC, Lim S. Long-term supportive housing is associated with decreased risk for new HIV diagnoses among a large cohort of homeless persons in New York City. AIDS Behav. 2018;22:3083\u201390.","journal-title":"AIDS Behav"},{"key":"964_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.drugalcdep.2009.04.008","volume":"104","author":"BD Stein","year":"2009","unstructured":"Stein BD, Kogan JN, Sorbero M. Substance abuse detoxification and residential treatment among Medicaid enrolled adults: Rates and duration of subsequent treatment. Drug Alcohol Depend. 2009;104:66.","journal-title":"Drug Alcohol Depend"},{"key":"964_CR46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0740-5472(03)00039-4","volume":"24","author":"TL Mark","year":"2003","unstructured":"Mark TL, Dilornardo JD, Chalk M, Coffey R. Factors associated with the receipt of treatment following detoxification. J Subst Abuse Treat. 2003;24:299\u2013304.","journal-title":"J Subst Abuse Treat"},{"key":"964_CR47","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jsat.2020.01.017","volume":"112","author":"JR Morgan","year":"2020","unstructured":"Morgan JR, Wang J, Barocas JA, Jaeger JL, Durham NN, Babakhanlou-Chase H, Bharel M, Walley AY, Linas BP. Opioid overdose and inpatient care for substance use disorder care in Massachussets. J Subst Abuse Treat. 2020;112:42\u20138.","journal-title":"J Subst Abuse Treat"},{"key":"964_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1300\/J069v25n01_12","volume":"25","author":"RD Blondell","year":"2006","unstructured":"Blondell RD, Amadasu A, Servoss TJ, Smith SJ. Differences among those who complete and fail to complete inpatient detoxification. J Addict Dis. 2006;25:95\u2013104.","journal-title":"J Addict Dis"},{"key":"964_CR49","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1111\/add.15985","volume":"117","author":"A Borquez","year":"2022","unstructured":"Borquez A. Commentary on Savinkina et al.: reforming drug \u201cdetox\u201d centers-what will it entail and where do we begin? Addiction. 2022;117:2462\u20133. https:\/\/doi.org\/10.1111\/add.15985.","journal-title":"Addiction"},{"key":"964_CR50","unstructured":"Substance Abuse and Mental Health Services Administration. National survey of substance abuse treatment services (N-SSATS). Rockville: SAMHSA; 2019."},{"key":"964_CR51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","volume":"36","author":"R Mojtabai","year":"2019","unstructured":"Mojtabai R, Mauro C, Wall M, Barry C, Olfson M. Medication treatment for opioid use disorders in substance use treatment facilities. Health Aff. 2019;36:14\u201323.","journal-title":"Health Aff"},{"key":"964_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108921","volume":"144","author":"R Smart","year":"2023","unstructured":"Smart R, Kim JY, Kennedy S, Tang L, Allen L, Crane D, Mack A, Mohamoud S, Pauly N, Perez R, et al. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder. J Subst Abuse Treat. 2023;144: 108921. https:\/\/doi.org\/10.1016\/j.jsat.2022.108921.","journal-title":"J Subst Abuse Treat"},{"key":"964_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/prom.S297699","volume":"13","author":"N Sanger","year":"2022","unstructured":"Sanger N, Panesar B, Dennis M, Rosic T, Rodrigues M, Lovell E, Yang S, Butt M, Thabane L, Samaan Z. The inclusion of patients\u2019 reported outcomes to inform treatment effectiveness measures in opioid use disorder. A systematic review. Patient Relat Outcome Meas. 2022;13:113\u201330. https:\/\/doi.org\/10.2147\/prom.S297699.","journal-title":"Patient Relat Outcome Meas"},{"key":"964_CR54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/02791072.2011.587392","volume":"43","author":"SG Mitchell","year":"2011","unstructured":"Mitchell SG, Morioka R, Seisinger HS, Peterson JA, Kelly SM, Agar MH, Brown BS, O\u2019Grady KE, Schwartz R. Redefining retention: recover from the patient\u2019s perspective. J Psychoact Drugs. 2011;43:99\u2013107.","journal-title":"J Psychoact Drugs"},{"key":"964_CR55","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1037\/ort0000232","volume":"87","author":"J Dickson-Gomez","year":"2017","unstructured":"Dickson-Gomez J, Quinn K, Bendixen A, Johnson A, Nowicki K, Ko Ko T, Galletly C. Identifying variability in permanent supportive housing: a comparative effectiveness approach to measuring health outcomes. Am J Orthopsychiatry. 2017;87:414\u201324. https:\/\/doi.org\/10.1037\/ort0000232.","journal-title":"Am J Orthopsychiatry"},{"key":"964_CR56","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.drugalcdep.2006.12.019","volume":"89","author":"JD Wines","year":"2007","unstructured":"Wines JD, Saitz R, Horton NJ, Lloyd-Travaglini C, Samet JH. Overdose after detoxification: a prospective study. Drug Alcohol Depend. 2007;89:66.","journal-title":"Drug Alcohol Depend"},{"key":"964_CR57","first-page":"66","volume":"6","author":"J Dickson-Gomez","year":"2023","unstructured":"Dickson-Gomez J, Weeks M, Green D, Boutouis S, Galletly C, Christenson E. Insurance barriers to substance use disorder treatment after passage of menal health and addiciton parity laws and the Affordable Care Act: a qualitative analysis. Drug Alcohol Abuse Rep. 2023;6:66.","journal-title":"Drug Alcohol Abuse Rep"},{"key":"964_CR58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/nuf.12256","volume":"53","author":"MJ Upvall","year":"2018","unstructured":"Upvall MJ, Bourgault AM. De-implementation: a concept analysis. Nurs Forum. 2018;53:376\u201382.","journal-title":"Nurs Forum"},{"key":"964_CR59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1200\/JCO.18.00589","volume":"37","author":"WE Norton","year":"2018","unstructured":"Norton WE, Chambers DA, Kramer BS. Conceptualizing de-implementation in cancer care delivery. J Clin Oncol. 2018;37:93\u20136.","journal-title":"J Clin Oncol"},{"key":"964_CR60","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13012-019-0960-9","volume":"15","author":"WE Norton","year":"2020","unstructured":"Norton WE, Chambers DA. Unpacking the complexities of de-implementing inappropriate health interventions. Implement Sci. 2020;15:66.","journal-title":"Implement Sci"},{"key":"964_CR61","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1177\/1077558716656970","volume":"74","author":"CH Colla","year":"2016","unstructured":"Colla CH, Mainor AJ, Hargreaves C, Sequist T, Morden N. Interventions aimed at reducing use of low-value health services: a systematic review. Med Care Res Rev. 2016;74:507\u201350.","journal-title":"Med Care Res Rev"},{"key":"964_CR62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/09540121.2020.1739207","volume":"32","author":"JA Kelly","year":"2020","unstructured":"Kelly JA, Amirkhanian YA, Walsh JL, Brown KD, Quinn KG, Petroll AE, Pearson BM, Rosado AN, Ertl T. Social network intervention to increase pre-exposure prophylaxis (PrEP) awareness, interest, and use among African American men who have sex with men. AIDS Care. 2020;32:40\u20136. https:\/\/doi.org\/10.1080\/09540121.2020.1739207.","journal-title":"AIDS Care"},{"key":"964_CR63","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s10461-020-03117-4","volume":"25","author":"J Clark","year":"2021","unstructured":"Clark J, Reisner S, Perez-Brumer A, Huerta L, Sanchez H, Moriarty K, Luque MM, Okochi H, Salazar X, Mimiaga M, et al. TransPrEP: results from the pilot study of a social network-based intervention to support PrEP adherence among transgender women in Lima. Peru AIDS Behav. 2021;25:1873\u201383. https:\/\/doi.org\/10.1007\/s10461-020-03117-4.","journal-title":"Peru AIDS Behav"},{"key":"964_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065812","volume":"8","author":"SA Strathdee","year":"2013","unstructured":"Strathdee SA, Abramovitz D, Lozada R, Martinez G, Rangel MG, Vera A, Staines H, Magis-Rodriguez C, Patterson TL. Reductions in HIV\/STI incidence and sharing of injection equipment among female sex workers who inject drugs: results from a randomized controlled trial. PLoS ONE. 2013;8: e65812. https:\/\/doi.org\/10.1371\/journal.pone.0065812.","journal-title":"PLoS ONE"},{"key":"964_CR65","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1007\/s10461-013-0563-4","volume":"17","author":"IF Hoffman","year":"2013","unstructured":"Hoffman IF, Latkin CA, Kukhareva PV, Malov SV, Batluk JV, Shaboltas AV, Skochilov RV, Sokolov NV, Verevochkin SV, Hudgens MG, et al. A peer-educator network HIV prevention intervention among injection drug users: results of a randomized controlled trial in St. Petersburg, Russia. AIDS Behav. 2013;17:2510\u201320. https:\/\/doi.org\/10.1007\/s10461-013-0563-4.","journal-title":"AIDS Behav"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00964-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00964-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00964-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T16:08:20Z","timestamp":1709050100000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00964-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00964-5","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"17 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}